Akari Therapeutics, Plc (AKTX) Stock: A Biotech Stock That’s Seeing Declines


Akari Therapeutics, Plc (AKTX) is headed down in the market today. The stock, one that is focused in the biotech industry, is presently priced at $4.28 after a move down of -26.21% so far today. As it relates to biotechnology stocks, there are quite a few aspects that have the ability to generate declines in the market. One of the most common is news. Here are the most recent stories associated with AKTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-14-19 10:06AM What Kind Of Shareholders Own Akari Therapeutics, Plc (NASDAQ:AKTX)?
07:47AM The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering
Mar-13-19 02:35PM These 4 Tech Stocks Are On The Rise On Wednesday (3/13/19)
10:35AM Akari Therapeutics’ stock rockets on massive volume after ‘successful’ pre-IND FDA meeting
08:30AM Positive FDA Meeting Outlines Path Ahead for Akari Therapeuticss Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

However, when making an investing decision, investors should focus on far more than news, especially in the speculative biotech industry. Here’s what’s happing when it comes to Akari Therapeutics, Plc.

The Performance That We’ve Seen From AKTX

Although a decline in a single session, like the fall that we’re seeing from Akari Therapeutics, Plc might cause fear in some investors, that by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always a good idea to look into trends experienced by the stock further out than a single trading session. When it comes to AKTX, here are the returns that investors have seen:

  • Past Seven Days – In the past 5 trading sessions, AKTX has generated a price change that amounts to 220.69%.
  • Monthly – The return on investment from Akari Therapeutics, Plc throughout the past 30 days has been 210.28%.
  • Past Quarter – In the past three months, the company has generated a ROI that works out to 219.51%
  • Past Six Months – Throughout the past six months, investors have seen a performance that equates to 177.80% from the stock.
  • This Year So Far – Since the close of last year AKTX has generated a return of 269.43%.
  • Full Year – Finally, over the past year, we’ve seen movement of 151.08% from AKTX. In this period, the stock has sold at a high price of -53.48% and a low price of 174.36%.

Ratios Worth Watching

Looking at various ratios associated with a stock can give prospective traders a look of how risky and/or rewarding a stock pick might be. Here are some of the important ratios to consider when digging into AKTX.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors have a belief that the value of the stock is headed for declines. Throughout the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also see quite a few short squeezes in the sector. Nonetheless, in regard to Akari Therapeutics, Plc, the stock’s short ratio clocks in at 0.09.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due with only quick assets or current assets. Because many biotech many companies are heavily reliant on continued support from investors, these ratios can be upsetting. However, several gems in the biotechnology sector come with good quick and current ratios. In terms of AKTX, the quick and current ratios total up to 2.00 and 2.00 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio works out to 0.41.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotechnology stock, this is a very important ratio to look into. In this case, the cash to share value ratio comes to 0.

How Analysts Feel About Akari Therapeutics, Plc

Although it’s never a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their thoughts when validating your own opinions when it comes to making investment decisions in the biotech space. Below are|Here are} the most recent moves that we’ve seen from analysts when it comes to AKTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-04-19 Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18 Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17 Upgrade William Blair Mkt Perform → Outperform
May-31-17 Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17 Reiterated Chardan Capital Markets Sell $6.50 → $5

What Institutions And Insiders Think Of Akari Therapeutics, Plc

One thing that I’ve learned in my brief period on Earth has been that smart investors tend to follow the moves made by big money investors. In general, investors that are looking to play it relatively safe will keep their eyes on moves made by institutions as well as those on the inside. So, where is the big money when it comes to AKTX? Here’s the information:

  • Institutions – As it stands now, institutions own 5.60% of the company. Nonetheless, it is important to consider that institutional ownership has seen a move of -16.58% over the past 3 months.
  • Insider Holdings – as it relates to insiders, those close to the company currently hold 57.08% of Akari Therapeutics, Plc. Their ownership of the company has moved 0.00% throughout the past quarter.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 15.63M shares of Akari Therapeutics, Plc outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AKTX has a float of 7.98M.

It’s also important to look at the short percent. After all, if a high portion of the float available for trading is sold short, the overall feeling among traders is that the company is going to lose value. As far as AKTX, the short percentage of the float totals up to 2.01%. In general, concerning short percent of the float is considered to be anything over 40%. In my research, I’ve seen that a short percent of the float over 26% is probably going to be a risky play.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.00. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, AKTX has generated revenue in the amount of $0 with earnings coming in at 39.20%. On a quarter over quarter basis, earnings have seen movement of 73.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was made by a human and human beings actually play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at information? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here